BiotechTube
KlyneAI

KlyneAI

San Francisco, United States· Est.
klyne.ai
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

KlyneAI operates as an AI-powered CRO, offering a suite of computational tools designed to drastically reduce the cost and time of early-stage drug discovery. Its platform combines active learning, ML-enhanced docking (KlyneDock), free energy perturbation alternatives (HYRDA, Klyne FEP), and generative AI to screen ultra-large chemical libraries and optimize lead compounds. The company's value proposition centers on making advanced in silico techniques accessible and economical for resource-constrained research organizations.

AI / Machine LearningDrug Discovery

Technology Platform

A modular AI-powered suite for computational drug discovery, including Ultra-Large Virtual Screening, Active Learning for efficient screening, KlyneDock (ML-enhanced docking), HYRDA and Klyne FEP for cost-effective affinity prediction, and Generative AI for multi-parameter lead optimization.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The growing demand for cost-effective, outsourced computational drug discovery from virtual biotechs and academic labs presents a significant addressable market.
The expansion of purchasable chemical libraries into the billions of compounds creates a necessity for efficient screening tools like KlyneAI's.
Successful validation through client projects could lead to partnerships with larger pharmaceutical companies seeking to augment their internal capabilities.

Risk Factors

The company's claims of superior performance and cost savings require continuous validation in competitive benchmarks and real-world projects to build and maintain credibility.
It operates in a crowded and well-funded competitive landscape against both large software vendors and integrated AI-biotech companies.
Its reliance on a budget-conscious customer base makes it vulnerable to downturns in biotech funding.

Competitive Landscape

KlyneAI competes in the AI-driven drug discovery space, facing competition from integrated AI-biotechs (e.g., Recursion, Exscientia, Insilico Medicine), enterprise software providers (e.g., Schrödinger, Dassault Systèmes), and other specialized CROs. Its primary differentiation is a focused value proposition on being the lowest-cost provider of high-performance in silico services for early-stage discovery.

More companies in AI / Machine Learning →More companies in United States →